---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-26-000022"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:45:26.929446+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Spyre Therapeutics reports Q4 2025 net loss of $62.5M; cash $756.5M; Phase 2 readouts expected Q2/Q4 2026

## Summary
- Q4 2025 net loss $62.5M (vs $56.3M Q4 2024); R&D expense $44.6M (vs $50.5M).
- Cash, cash equivalents, and marketable securities $756.5M at Dec 31, 2025; raised $316.2M gross in Oct 2025 public offering.
- On track for 6 proof-of-concept readouts in 2026: SKYLINE Part A (IBD) data expected Q2 2026; SKYWAY trial (RA, PsA, axSpA) data expected Q4 2026.
- Appointed Kate Tansey Chevlen as Chief Commercial Officer.
- Expected cash runway into second half of 2028.

## SEC filing metadata
- accession: 0001636282-26-000022
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000022/0001636282-26-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000022/syre-20260219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-26-000022
- JSON: https://secwatch.observer/filing/0001636282-26-000022.json
- Plain text: https://secwatch.observer/filing/0001636282-26-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.